Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methamidophos is a highly toxic organophosphate insecticide and acaricide used to control a variety of horticultural and agricultural pests, including aphids and flea beetles. It acts as a potent acetylcholinesterase inhibitor, disrupting nerve function in insects (and humans) by preventing the breakdown of acetylcholine at synaptic junctions. Methamidophos is rapidly absorbed through the stomach, lungs, and skin in humans and is primarily eliminated via urine. Due to its high acute toxicity (classified as WHO Toxicity Class 1b), its use has been phased out or banned in many countries[2][4][7]. The compound is also known for causing severe cholinergic symptoms upon exposure due to its mechanism of action[1][5]. Its parent chemical is acephate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methamidophos.